Search

Displaying results 4931 - 4940 of 10000 in total
  1. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

  2. Drug

    INKP-102

    go.drugbank.com/drugs/DB05326
    Experimental

    INKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.

  3. Drug

    Dimethyltryptamine

    go.drugbank.com/drugs/DB01488
    IllicitInvestigational

    An N-methylated indoleamine derivative, a serotonergic hallucinogen found in several plants, especially Prestonia amazonica (Apocynaceae) and in mammalian brain, blood, and urine. … It apparently acts as an agonist at some types of serotonin receptors and an antagonist at others.

    Synonyms: N,N-dimethyltryptamine, N,N-dimethyl-1H-indole-3-ethylamine
  4. Drug

    Diodone

    go.drugbank.com/drugs/DB13568
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Imidapril

    go.drugbank.com/drugs/DB11783
    Investigational

    Imidapril has been investigated for the treatment of Kidney, Polycystic, Autosomal Dominant.

    Categories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    Delafloxacin

    go.drugbank.com/drugs/DB11943
    ApprovedInvestigational

    Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, … It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.

  7. Drug

    Pegpleranib

    go.drugbank.com/drugs/DB06325
    Investigational

  8. Drug

    Imexon

    go.drugbank.com/drugs/DB05003
    Investigational

    Imexon is a cyanoaziridine derivative. Imexon is a thiol-binding small molecule which induces mitochondrial oxidation, a loss of membrane potential and cytochrome C, leading to apoptosis.

  9. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)). … POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD).

  10. Drug

    Milvexian

    go.drugbank.com/drugs/DB16233
    Investigational

    Milvexian is under investigation in clinical trial NCT03766581 (A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel).